Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobovax Study
NCT05057169Phase 4Completed
- Sponsor
- The University of Hong Kong
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of tozinameran, coronavac in coronavirus disease 2019 (COVID-19), sponsored by The University of Hong Kong. Started Nov 2021; status: completed.
02
Drugs
tozinamerancoronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05057169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057169.